title: Discontinued in 2013: oncology drugs.
abstract: Introduction: Attrition in clinical development is widely recognised as a key factor negatively impacting overall R&D efficiency. Gaining an understanding of the reasons for candidate failure may lead to improvements in success rates and return on R&D investment. Areas covered: This report provides an analysis of reasons for discontinuation of development of 40 drugs dropped from the global oncology pipeline in 2013 - the largest number of terminations reported since this annual analysis began in 2005. The article also provides discussion on the observations in the context of contemporary views of anticancer drug development. Expert opinion: Twelve drugs (30% of the 2013 discontinuations) failed in Phase III development. None of the pivotal trials investigating these agents incorporated molecular biomarkers for patient stratification. The largest number of drug terminations (20 out of 40) occurred in Phase I development with reasons for termination commonly reported as strategic or undisclosed. Raising the bar in terms of requirements for progression from preclinical development, including the identification of robust pharmacodynamic biomarkers and biomarkers potentially predictive of clinical benefit may lead to an increase in success rates in clinical development and of overall R&D efficiency.
authors.affiliation: Drug Development Office, Cancer Research UK , Angel Building, 407 St John Street, London EC1V 4AD , UK +44 203 469 6900 ; robert.williams@cancer.org.uk.
authors.forename: Robert
authors.initials: R
authors.lastname: Williams
keywords: 4SC-203; ANX-514; ASG-5ME; ASP-9603; AZD-8330; Allovectin-7; BMS-582644; CP-4055; CS-7017; E-6201; EMD-121974; IMC-RON8; IPI-504; KHK-2866; KW-2450; LY-2334737; LY-2523355; LY-2603618; LY-3007113; LY-317615; MEDI-575; OSI-027; PF-4605412; PR1 vaccine; PWT-33597; RG-7112; RG-7160; RG-7414; RG-7420; SAR-240550; SAR-302503; SAR-402674; SGN-75; TAK-441; TAK-448; TAK-960; TAS-266; YM-155; ZIO-201; brivanib alaninate; cilengitide; efatutazone; elacytarabine; enzastaurin; fedratinib; imgatuzumab; iniparib; litronesib; narnatumab; palifosfamide; parsatuzumab; rabusertib; retaspimycin; sepantronium bromide; talactoferrin α; tovetumab; velimogene aliplasmid; vorsetuzumab mafodotin